Gilead Sciences analysis shows remdesivir reduced coronavirus death risk


Gilead Sciences Inc said on Friday an analysis showed its antiviral remdesivir helped reduce the risk of death in severely ill COVID-19 patients, but cautioned that rigorous clinical trials were needed to confirm the benefit. Remdesivir has been at the forefront of the global battle against Covid-19 after the intravenously administered medicine helped shorten hospital recovery times, according to data in April from a separate U.

S. government trial. That study showed a trend toward better survival for remdesivir but the difference was.....

This article is no longer available in our repository.

There could be multiple reasons for this.